Glycogen synthase kinase-3β: A prognostic marker and a potential therapeutic target in human bladder cancer

Clinical Cancer Research

Volumn 16, Issue 21, 2010, Pages 5124-5132

  Naito, Sei ^a   Bilim, Vladimir ^a   Yuuki, Kaori ^a   Ugolkov, Andrey ^b   Motoyama, Teiichi ^a   Nagaoka, Akira ^a   Kato, Tomoyuki ^a   Tomita, Yoshihiko ^a  

^a YAMAGATA UNIVERSITY   (Japan)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; GLYCOGEN SYNTHASE KINASE 3BETA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER INHIBITION; CANCER STAGING; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; URINARY TRACT CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 78049483997     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0275     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Sternberg CN, Yagoda A, Scher HI, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 1988;139:461-9.
3. Siefker-Radtke AO, Walsh GL, Pisters LL, et al. Is there a role for surgery in the management of metastatic urothelial cancer? The M.D. Anderson experience. J Urol 2004;171:145-8.
4. Woodgett JR, Cohen P. Multisite phosphorylation of glycogen synthase. Molecular basis for the substrate specificity of glycogen synthase kinase-3 and casein kinase-II (glycogen synthase kinase-5). Biochim Biophys Acta 1984;788:339-47.
5. Embi N, Rylatt DB, Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 1980;107:519-27.
6. de Groot RP, Auwerx J, Bourouis M, Sassone-Corsi P. Negative regulation of Jun/AP-1: conserved function of glycogen synthase kinase 3 and the Drosophila kinase shaggy. Oncogene 1993;8:841-7. (Pubitemid 23087414)
7. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000;14:2501-14.
8. Tullai JW, Chen J, Schaffer ME, Kamenetsky E, Kasif S, Cooper GM. Glycogen synthase kinase-3 represses cyclic AMP response element-binding protein (CREB)-targeted immediate early genes in quiescent cells. J Biol Chem 2007;282:9482-91.
9. Beals CR, Sheridan CM, Turck CW, Gardner P, Crabtree GR. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science 1997;275:1930-4.
10. Chu B, Zhong R, Soncin F, Stevenson MA, Calderwood SK. Transcriptional activity of heat shock factor 1 at 37 degrees C is repressed through phosphorylation on two distinct serine residues by glycogen synthase kinase 3 and protein kinases Cα and Cζ. J Biol Chem 1998;273:18640-6.
11. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998;12:3499-511.
12. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P. Binding of GSK3β to the APC-β-catenin complex and regulation of complex assembly. Science 1996;272:1023-6.
13. Ougolkov AV, Bone ND, Fernandez-Zapico ME, Kay NE, Billadeau DD. Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor κB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood 2007;110:735-42.
14. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD. Glycogen synthase kinase-3β participates in nuclear factor κB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 2005;65:2076-81.
15. Ougolkov AV, Fernandez-Zapico ME, Bilim VN, Smyrk TC, Chari ST, Billadeau DD. Aberrant nuclear accumulation of glycogen synthase kinase-3β in human pancreatic cancer: association with kinase activity and tumor dedifferentiation. Clin Cancer Res 2006;12:5074-81.
16. Shakoori A, Ougolkov A, Yu ZW, et al. Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun 2005;334:1365-73.
17. Shakoori A, Mai W, Miyashita K, et al. Inhibition of GSK-3 β activity attenuates proliferation of human colon cancer cells in rodents. Cancer Sci 2007;98:1388-93.
18. Cao Q, Lu X, Feng YJ. Glycogen synthase kinase-3β positively regulates the proliferation of human ovarian cancer cells. Cell Res 2006;16:671-7.
19. Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA, Chen H. Inactivation of glycogen synthase kinase-3β, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Mol Cancer Ther 2007;6:1151-8. (Pubitemid 46554586)
20. Miyashita K, Kawakami K, Nakada M, et al. Potential therapeutic effect of glycogen synthase kinase 3β inhibition against human glioblastoma. Clin Cancer Res 2009;15:887-97.
21. Liao X, Zhang L, Thrasher JB, Du J, Li B. Glycogen synthase kinase-3β suppression eliminates tumor necrosis factor-related apoptosisinducing ligand resistance in prostate cancer. Mol Cancer Ther 2003;2:1215-22.
22. Salas TR, Kim J, Vakar-Lopez F, et al. Glycogen synthase kinase-3 β is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem 2004;279:19191-200.
23. Bilim V, Ougolkov A, Yuuki K, et al. Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma. Br J Cancer 2009;101:2005-14.
24. Tomita Y, Watanabe H, Kobayashi H, et al. Expression of intercellular adhesion molecule-1 on transitional cell cancer. Possible significance in immunity against tumor cells. Am J Pathol 1993;143:191-8.
25. Bilim V, Kasahara T, Noboru H, Takahashi K, Tomita Y. Caspase involved synergistic cytotoxicity of bcl-2 antisense oligonucleotides and adriamycin on transitional cell cancer cells. Cancer Lett 2000;155:191-8.
26. Bhat R, Xue Y, Berg S, et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 2003;278:45937-45.
27. Coghlan MP, Culbert AA, Cross DA, et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 2000;7:793-803.
28. Martinez A, Alonso M, Castro A, Pérez C, Moreno FJ. First non-ATP competitive glycogen synthase kinase 3 β (GSK-3β) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem 2002;45:1292-9.
29. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997;158:62-7.
30. Raj GV, Herr H, Serio AM, et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 2007;177:1283-6.
31. Kotliarova S, Pastorino S, Kovell LC, et al. Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-κB, glucose regulation. Cancer Res 2008;68:6643-51.
32. Tas SW, Vervoordeldonk MJ, Tak PP. Gene therapy targeting nuclear factor-κB: towards clinical application in inflammatory diseases and cancer. Curr Gene Ther 2009;9:160-70.
33. Levidou G, Saetta AA, Korkolopoulou P, et al. Clinical significance of nuclear factor (NF)-κB levels in urothelial carcinoma of the urinary bladder. Virchows Arch 2008;452:295-304.
34. Stehlik C, de Martin R, Kumabashiri I, Schmid JA, Binder BR, Lipp J. Nuclear factor (NF)-κB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor α-induced apoptosis. J Exp Med 1998;188:211-6.
35. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNFα-induced apoptosis. Genes Dev 1999;13:382-7.
36. Bilim VN, Tomita Y, Kawasaki T, Takeda M, Takahashi K. Variable Bcl-2 phenotype in benign and malignant lesions of urothelium. Cancer Lett 1998;128:87-92.